Alembic Pharmaceuticals Limited
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Alembic Pharmaceuticals Limited generated cash of $8,032,000,000, which is more than the previous year. Cash used in financing activities reached the amount of -$4,378,700,000 last year. Net change in cash is therefore $447,300,000.
Cash Flow
| 2011 | 961.81M | -568.07M | -481.47M |
|---|---|---|---|
| 2012 | 1.40B | -563.89M | -435.59M |
| 2016 | 9.30B | -3.10B | -1.95B |
| 2018 | 3.12B | -8.84B | 5.02B |
| 2020 | 4.49B | -7.31B | 1.54B |
| 2021 | 14.63B | -8.38B | -5.97B |
| 2023 | 7.23B | -4.47B | -2.61B |
| 2024 | 8.03B | -3.20B | -4.37B |
APLLTD.NS Cash Flow Statement (2011 – 2023)
| 2023 | 2022 | 2020 | 2019 | 2017 | 2015 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 754.8M | 610.9M | 718.4M | 1.99B | 1.53B | 268.25M | 62.89M | 150.63M |
Operating activities | ||||||||
Net income | 6.15B | 3.54B | 13.68B | 9.99B | 5.41B | 9.35B | 1.30B | 853.87M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 2.72B | 2.75B | 1.83B | 1.57B | 1.05B | 722.13M | 336.49M | 295.91M |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | 390.5M | -2.22B | 5.10B | -3.58B | -1.84B | 46M | 0 | 0 |
Inventories | -1.68B | 1.34B | -2.98B | -2.20B | -1.01B | -1.94B | -395.09M | -62.86M |
Accounts payable | 560.4M | -281.7M | 452.7M | -211.1M | 2.58B | 2.64B | 0 | 0 |
Cash generated by operating activities | 8.03B | 7.23B | 14.63B | 4.49B | 3.12B | 9.30B | 1.40B | 961.81M |
Investing activities | ||||||||
Purchases Of Investments | -83.2M | -70M | -1.86B | -15.2M | 0 | -81.27M | 0 | 0 |
Investments In Property Plant And Equipment | -3.27B | -4.43B | -6.59B | -7.34B | -8.21B | -3.03B | -612.56M | -625.37M |
Acquisitions Net | 0 | 18.7M | -4.6M | 6M | -784.1M | 1.3M | 0 | 0 |
Cash generated by investing activities | -3.20B | -4.47B | -8.38B | -7.31B | -8.84B | -3.10B | -563.89M | -568.07M |
Financing activities | ||||||||
Common Stock Issued | 0 | 0 | 7.34B | 0 | 0 | 0 | 0 | 110M |
Payments for dividends | -1.57B | -1.96B | 0 | -3.25B | -907.6M | -652.7M | -216.44M | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -2.05B | 58.7M | -3.79B | 1.60B | 6.19B | -1.32B | -514.39M | 0 |
Cash used in financing activities | -4.37B | -2.61B | -5.97B | 1.54B | 5.02B | -1.95B | -435.59M | -481.47M |
Net Change In Cash | 447.3M | 143.9M | 262.2M | -1.27B | -693.4M | 4.24B | 407.91M | -87.74M |
Cash at end of period | 1.20B | 754.8M | 980.6M | 718.4M | 837.4M | 4.50B | 470.80M | 62.89M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |